Antibody-drug conjugates focus draws global pharma attention to China
Antibody-drug conjugates (ADCs) represent a significant breakthrough in targeted cancer therapy. By blending the specificity of monoclonal antibodies with the potency of cytotoxic drugs, ADCs offer a targeted approach to cancer treatment, minimizing the damage to healthy cells.
China has become a major force in the advancement of this innovative field. Consequently, global pharma giants are paying attention to Chinese pharmaceutical firms in this context, says pharma analytics company GlobalData.
According to GlobalData’s Pharmaceutical Intelligence Center, between 2019 and 2023, 487 oncology-related deals (strategic alliances) took place in China. Interestingly, ADC therapies were involved in 11.7% (57) of these cases. The percentage of deals involving ADCs has grown from 4.1% in 2019 to 23.7% in 2023. This shows a significant interest in the development of ADCs in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze